Aemetis (NASDAQ:AMTX) Given Buy Rating at HC Wainwright

Aemetis (NASDAQ:AMTX)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a report released on Friday,Benzinga reports. They currently have a $28.00 price target on the specialty chemicals company’s stock.

Other analysts also recently issued reports about the company. StockNews.com raised Aemetis to a “sell” rating in a research note on Wednesday, July 31st. UBS Group lowered their price objective on Aemetis from $8.25 to $7.75 and set a “buy” rating for the company in a research note on Monday, August 19th. Ascendiant Capital Markets lowered their price objective on Aemetis from $20.00 to $19.00 and set a “buy” rating for the company in a research note on Tuesday, September 3rd. Finally, Truist Financial reaffirmed a “hold” rating and set a $3.50 price target (down from $4.00) on shares of Aemetis in a research report on Wednesday, July 31st. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, Aemetis presently has an average rating of “Moderate Buy” and a consensus target price of $12.95.

Aemetis Stock Down 4.4 %

NASDAQ:AMTX traded down $0.18 on Friday, hitting $3.89. The stock had a trading volume of 481,922 shares, compared to its average volume of 805,687. The business’s fifty day moving average is $2.77 and its 200 day moving average is $3.06. The company has a market cap of $193.49 million, a PE ratio of -1.72 and a beta of 1.23. Aemetis has a 52 week low of $2.10 and a 52 week high of $7.03.

Aemetis (NASDAQ:AMTX) last announced its quarterly earnings results on Tuesday, November 12th. The specialty chemicals company reported ($0.38) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.47) by $0.09. The firm had revenue of $81.44 million during the quarter, compared to the consensus estimate of $77.79 million. During the same quarter in the previous year, the company posted ($0.59) EPS. Equities analysts predict that Aemetis will post -2.1 earnings per share for the current fiscal year.

Institutional Trading of Aemetis

A number of institutional investors and hedge funds have recently modified their holdings of the business. SG Americas Securities LLC purchased a new stake in Aemetis in the first quarter worth $60,000. Rhumbline Advisers increased its position in Aemetis by 2,837.1% in the second quarter. Rhumbline Advisers now owns 52,309 shares of the specialty chemicals company’s stock worth $157,000 after buying an additional 50,528 shares during the last quarter. Susquehanna Fundamental Investments LLC increased its position in Aemetis by 287.4% in the second quarter. Susquehanna Fundamental Investments LLC now owns 126,078 shares of the specialty chemicals company’s stock worth $379,000 after buying an additional 93,536 shares during the last quarter. State Board of Administration of Florida Retirement System purchased a new stake in Aemetis in the first quarter worth $84,000. Finally, Bank of New York Mellon Corp purchased a new stake in Aemetis in the second quarter worth $306,000. 27.02% of the stock is owned by hedge funds and other institutional investors.

About Aemetis

Aemetis, Inc operates as a renewable natural gas and renewable fuels company. It operates through three segments: California Ethanol, California Dairy Renewable Natural Gas, and India Biodiesel. The company focuses on the operation, acquisition, development, and commercialization of technologies to produce low and negative carbon intensity renewable fuels that replace fossil-based products.